Acute Myeloid Leukemia
Conditions
Keywords
acute myeloid leukemia, genomic signatures, midostaurin, relapsed, refractory, PKC412
Brief summary
This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML.
Detailed description
Clinical trials have shown that the multi-kinase inhibitor midostaurin improves survival in patients with AML. The main objective of this study is to investigate its effect (in conjunction with cytarabine) on progression free survival, as well as overall survival and morphologic response rate in patients with relapsed or refractory AML. This study will also attempt to identify specific populations of patients with relapsed or refractory AML who best respond to treatment with midostaurin to enhance treatment planning.
Interventions
DRUGMidostaurin
Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant.
DRUGCytarabine
Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6. Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle.
Sponsors
Novartis Pharmaceuticals
University of Florida
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All patients will receive midostaurin and cytarabine.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent obtained from the subject prior to registration on the study and the ability for the subject to adhere to the study visit schedule and all the study-related procedures. * A diagnosis of relapsed or refractory AML. For the purpose of this study, refractory AML is defined as failure to achieve CR after one cycle of induction chemotherapy and relapsed AML is defined as any evidence of disease recurrence after achieving CR of any duration. * Both males and females ≥ eighteen years of age * Karnofsky Performance Status of ≥ 70% or Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (unless poor performance status is related to the disease). * Adequate organ function defined as: * AST and ALT \< 2.5 times the upper limit of normal (ULN), * Serum bilirubin \< 2.5 x ULN, and * Serum creatinine \< 1.5 mg/dL or creatinine clearance \> 50 mL/min. * Laboratory values can be outside of this range if secondary to AML disease. * An ejection fraction of \> 45% confirmed by echocardiogram. * Life expectancy of greater than one month. * Subjects who previously received midostaurin are allowed if the last dose of midostaurin was given ≥ six months prior to disease relapse. * Females who are non-pregnant and non-nursing. * Females of reproductive age and males must agree to avoid getting pregnant or to father a child while on therapy and for five months after the last dose of chemotherapy. * Women of child-bearing potential (WOCBP) must either agree to continued abstinence from heterosexual intercourse or begin one of the following acceptable methods of birth control: IUD, tubal ligation, or partner must use a latex condom during any sexual contact, even if the partner has undergone a successful vasectomy. Hormonal contraception is an inadequate method of birth control. * Males must use a latex condom during any sexual contact with WOCBP, even if they have undergone a successful vasectomy (while on therapy and for five months after the last dose of chemotherapy)
Exclusion criteria
* Age ≥ of seventy-six years. * Subjects with the inability to swallow oral medications. * Clinical evidence of active CNS leukemia. * A medical history of receiving an allogeneic hematopoietic stem cell transplantation (HSCT). * Subjects must not have any uncontrolled or intercurrent illness including, but not limited to, * ongoing or active infection, * symptomatic congestive heart failure, * unstable angina pectoris, * cardiac arrhythmia, * myocardial infarction within three months, * poorly controlled hypertension, * uncontrolled diabetes, or psychiatric illness/social situation that would limit compliance with protocol requirements. * Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least five months after the last dose of chemotherapy. * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PKC412. * Previous therapy with midostaurin within six months prior to relapse. * History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. * Prisoners or subjects who are involuntarily incarcerated. * Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness. * Subjects demonstrating an inability to comply with the study and/or follow-up procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | Up to 6 months | Compare the progression free survival of patients receiving midostaurin and cytarabine to that historically achieved in patients receiving cytarabine alone |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology for Adverse Events(CTCAE) v4.0 | Up to 2.5 years | Assess the incidence and severity of toxicities of midostaurin and cytarabine using CTCAE v4.0 |
| Overall survival | Up to 3.5 years | Compare the overall survival of patients receiving midostaurin and cytarabine to that historically achieved in patients receiving cytarabine alone |
| Morphologic response rate | Up to 6 months | Compare the morphologic response rate (using International Working Group 2003 criteria) of patients receiving midostaurin and cytarabine to that historically achieved in patients receiving cytarabine alone |
Countries
United States
Outcome results
None listed